Meeting
2023 ASCO Genitourinary Cancers Symposium
Physician preferences for nonmetastatic castration-resistant prostate cancer treatments: A discrete choice experiment among men in mainland China.
Authors
Yu Fan
Peking University First Hospital, Beijing, China
Yu Fan , Shiyun Huang , Rui Xu , Zhisong He
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer - Advanced
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 88)
DOI
10.1200/JCO.2023.41.6_suppl.88
Abstract #
88
Poster Bd #
D8
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Efficacy and safety outcomes of darolutamide in patients with nonmetastatic castration-resistant prostate cancer with comorbidities and concomitant medications from ARAMIS.
First Author: Karim Fizazi
Poster
2022 ASCO Gastrointestinal Cancers Symposium
DKN-01 and tislelizumab ± chemotherapy as a first-line (1L) and second-line (2L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish Trial.
First Author: Samuel J Klempner
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Safety and efficacy of ONO-4578 plus nivolumab in metastatic colorectal cancer.
First Author: Akihito Kawazoe
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A retrospective analysis of the efficacy and safety of imatinib in elderly patients with advanced gastrointestinal stromal tumor.
First Author: Takahito Awatsu